Cirrhosis | Clinical Medicine

Cirrhosis | Main Ideas and Lessons

What cirrhosis is and how it develops

Cirrhosis is advanced, generally irreversible liver fibrosis that reduces normal liver function and can cause portal hypertension.

The process begins with repeated, chronic liver injury:

1. Hepatocytes are damaged over time.
2. Stellate cells deposit fibrous connective tissue, producing fibrosis.
3. As the liver tries to regenerate, it forms nodules that distort its normal architecture.
4. Fibrosis and nodules impair liver function and obstruct blood flow through the liver, raising pressure in the portal venous system.

Early cirrhosis may be compensated and cause few or no symptoms. Decompensated cirrhosis is marked by complications such as ascites, variceal bleeding, hepatic encephalopathy, or kidney injury.

Causes of chronic liver injury

The lecture groups causes into several broad categories:

• Direct injury to liver cells

  • Alcohol-related liver disease, which can cause fat accumulation (steatosis), inflammation, and progressive fibrosis.
  • Medication- or toxin-related injury.
  • Autoimmune hepatitis; the lecture mentions antinuclear antibodies, smooth-muscle antibodies, elevated IgG, and anti-LKM1 as possible diagnostic clues.
  • Chronic hepatitis B or C. Relevant history may include unprotected sex, intravenous drug use, shared or contaminated needles, or past blood transfusions.
  • Metabolic conditions:
    • Hemochromatosis: excess iron, which may also affect the pancreas and heart. Associated clues include diabetes, bronze-colored skin, and cardiomyopathy.
    • Wilson disease: excess copper. Possible clues include Kayser–Fleischer rings and movement abnormalities.
    • Alpha-1 antitrypsin deficiency: can be associated with emphysema in younger people and liver disease.
    • Nonalcoholic fatty liver disease and steatohepatitis, associated with metabolic risk factors such as obesity, hypertension, and hyperlipidemia.

• Vascular congestion or impaired drainage

  • Chronic right-sided heart failure can raise venous pressure and cause liver congestion and injury.
  • Budd–Chiari syndrome results from obstruction or clotting in the hepatic veins. The lecture notes associations with malignancy, clotting predispositions such as factor V Leiden or prothrombin mutations, and polycythemia.

• Chronic biliary disease

  • Long-standing inflammation or obstruction of bile ducts can cause bile to accumulate and damage the liver.
  • Primary biliary cholangitis (PBC) mainly affects intrahepatic bile ducts; antimitochondrial antibodies are a clue.
  • Primary sclerosing cholangitis (PSC) can affect intrahepatic and extrahepatic ducts and is associated with ulcerative colitis.
  • Jaundice and itching may occur with biliary disease.

Major complications

Portal hypertension and portosystemic shunting

Fibrosis compresses small portal vessels, making it harder for blood to pass through the liver. Portal pressure rises, and blood may be redirected through portosystemic shunts. Shunted blood bypasses normal liver processing.

• Hepatic encephalopathy: Ammonia and other toxins can accumulate when the liver cannot clear them or when blood bypasses the liver. Symptoms range from confusion and personality changes to severe altered mental status. Asterixis (a flapping hand tremor) is a characteristic sign. Gastrointestinal bleeding, spontaneous bacterial peritonitis (SBP), and TIPS can trigger or worsen encephalopathy.
• Esophageal varices: Elevated portal pressure enlarges veins near the lower esophagus. Rupture can cause life-threatening upper gastrointestinal bleeding, presenting as vomiting blood or dark, tarry stools.
• Ascites: Increased portal pressure pushes fluid into the abdominal cavity. Low albumin from impaired liver synthesis can contribute. Ascites related to portal hypertension typically has a serum–ascites albumin gradient (SAAG) above 1.1.
• Spontaneous bacterial peritonitis (SBP): Bacteria can enter ascitic fluid and cause infection. Possible clues include abdominal pain, fever, or a sudden worsening of encephalopathy. An ascitic-fluid neutrophil count of 250 cells/mm³ or more supports SBP.
• Kidney injury and hepatorenal syndrome: Splanchnic vasodilation can reduce effective circulating blood volume. The body responds by activating systems that constrict renal blood vessels, reducing kidney perfusion and potentially causing acute kidney injury.

Loss of normal liver function

• Reduced albumin production contributes to fluid leaving the bloodstream and can worsen ascites.
• Impaired clotting-factor production can raise the INR and increase bleeding risk. Reduced thrombopoietin can also lower platelet counts.
• Reduced ammonia clearance can contribute to encephalopathy.
• Reduced estrogen metabolism can cause testicular atrophy, gynecomastia, palmar erythema, and spider angiomas.
• Impaired bilirubin processing and excretion can cause jaundice and yellowing of the eyes.

Hepatocellular carcinoma

Chronic inflammation and cirrhosis increase the risk of hepatocellular carcinoma (HCC). The lecture emphasizes surveillance with abdominal ultrasound approximately every six months, sometimes alongside alpha-fetoprotein (AFP) measurement.

Diagnosis and assessment

Diagnosis combines clinical findings, laboratory tests, and imaging. A liver biopsy can confirm cirrhosis by showing nodular fibrosis and may help identify its cause.

The lecture recommends considering:

• Blood tests: CBC, liver tests, PT/INR, and albumin.
  • AST and ALT may be elevated, particularly earlier in disease, but can be normal in advanced cirrhosis.
  • Elevated bilirubin, prolonged PT/INR, low albumin, and low platelets can support the diagnosis and indicate impaired liver function.
• Imaging: Abdominal ultrasound with elastography can identify structural changes and increased liver stiffness, though it is not definitive by itself.
• Biopsy: Useful when confirmation is needed or the underlying cause remains unclear.
• Assessment for decompensation: Look for ascites, SBP, esophageal varices, hepatorenal syndrome, and hepatic encephalopathy.
• Ascites evaluation: Perform paracentesis for new ascites or when a patient with cirrhosis is hospitalized with ascites. Use SAAG to assess for portal hypertension and the ascitic neutrophil count to assess for SBP. A neutrophil count of at least 250 cells/mm³ supports SBP; treatment need not wait for culture results.
• Possible variceal bleeding: Upper endoscopy (EGD) can identify and treat bleeding varices.
• Possible encephalopathy: A raised ammonia level may support the diagnosis, but a normal level does not rule it out. Clinical changes from baseline are important.
• Possible kidney injury: Check kidney function and urine studies when creatinine rises or urine output falls.

Treatment and management

Management focuses on addressing the underlying cause, reducing further liver injury, treating complications, and assessing the need for transplantation.

• Ascites

  • Restrict sodium, with the lecture recommending about 2 g per day.
  • Use spironolactone and furosemide; the lecture describes higher spironolactone doses with lower furosemide doses.
  • For large-volume paracentesis, give albumin when more than 5 L of fluid is removed to reduce risks such as hypotension and kidney injury.
  • Consider TIPS for refractory ascites requiring repeated procedures.

• SBP

  • Treat with antibiotics; ceftriaxone is presented as a usual first-line option, with ciprofloxacin also mentioned.

• Hepatic encephalopathy

  • Use lactulose to promote removal of ammonia through the gut.
  • Rifaximin can reduce ammonia-producing gut bacteria.
  • Look for triggers such as gastrointestinal bleeding, SBP, or a recent TIPS procedure.

• Hepatorenal syndrome

  • Identify and address triggers such as SBP, bleeding, dehydration, or large-volume fluid removal without albumin.
  • The lecture describes albumin together with medicines such as midodrine and octreotide to improve effective circulation and kidney perfusion.

• Variceal bleeding

  • Use octreotide to reduce splanchnic blood flow and portal pressure.
  • Give ceftriaxone as prophylaxis during an acute bleeding episode.
  • Perform endoscopy and band ligation once the patient is stable.
  • TIPS may be considered in selected cases.
  • Propranolol or nadolol may be used to reduce the risk of future bleeding.

• HCC surveillance

  • Perform abdominal ultrasound about every six months, with AFP monitoring as discussed in the lecture.

• Transplant assessment

  • The Child–Pugh score considers albumin, bilirubin, coagulation/INR, ascites, and encephalopathy.
  • The lecture highlights MELD-Na as a tool for estimating short-term risk and transplant urgency; its components include bilirubin, INR, creatinine, sodium, and dialysis status.

Speakers and sources featured

• Professor Zach Murphy, lecturer for Ninja Nerd, based on the video context.
• No other speakers or external sources are identified in the subtitles.